Figure 4
From: Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy
ACP and BCL act through GABAB, Glycine and metabotropic glutamatergic receptor signalling.
GABABR CGP54626 antagonist (a), Glycine receptor Strychnine antagonist (b), mGluR1/5R DHPG agonist (c) and mGluR2/3R (2R,4R)-APDC agonist (d) all blocked BCL and ACP protection of rat primary neuronal cells validating the action of these drugs on these pathways. Values are mean ± s.e.m. ***P < 0.001 versus Aβ, BCL or ACP; ANOVA with Dunnett's test. mGlu1/5R and mGlu2/3R: metabotropic glutamate group I and II receptors respectively.
